ⅢA-N2期非小细胞肺癌根治术后放疗疗效影响因素的研究进展

doi:10.3760/cma.j.cn113030-20190509-00171

摘要
图/表
参考文献(38)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要随着现代放疗技术的进步,术后放疗在根治术后 ⅢA-N2期非小细胞肺癌中的地位受到重视。目前,由于缺乏大规模前瞻性的随机对照研究,术后放疗的价值一直受到争议。大量回顾性研究证实术后放疗疗效与不同临床病理特征有很强的相关性,本文对影响术后放疗疗效的因素进行分析总结,探讨术后放疗获益亚组人群,实现精准的术后放疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	田翠孟
	李宝兰

关键词 ：癌,非小细胞肺/术后放射疗法, 治疗结果, 研究进展

Abstract：With the development of modern radiotherapy technology, the significance of postoperative radiotherapy in treating resectable stage ⅢA-N2 non-small cell lung cancer has been emphasized. At present, the value of postoperative radiotherapy has been controversial due to the lack of large-size prospective randomized controlled studies. A large number of retrospective studies have confirmed that the efficacy of postoperative radiotherapy is significantly correlated with different clinicopathological characteristics. In this article, the influencing factors of the efficacy of postoperative radiotherapy were analyzed, and the subgroup of patients receiving clinical benefits was discussed, aiming to achieve precise postoperative radiotherapy.

Key words： Carcinoma, non-small cell lung/postoperative radiotherapy Treatment outcome Research progress

收稿日期: 2019-05-09

通讯作者: 李宝兰,Email:libaolan1109@163.com

引用本文:

田翠孟,李宝兰. ⅢA-N2期非小细胞肺癌根治术后放疗疗效影响因素的研究进展[J]. 中华放射肿瘤学杂志, 2020, 29(10): 909-912.

Tian Cuimeng,Li Baolan. Research progress on clinical efficacy of postoperative radiotherapy for resectable pathological stage ⅢA-N2 non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 909-912.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20190509-00171 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2020/V29/I10/909

[1] Kim KL, Ahn YC, Lim DH, et al. Analyses on prognostic factors following tri-modality therapy for stage Ⅲ a non-small cell lung cancer[J]. Lung Cancer, 2007, 55(3):329-336. DOI:10.1016/j.lungcan.2006.10.024.
[2] Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer:evidence for a subclassification and implications[J]. J Clin Oncol, 2000, 18(16):2981-2989. DOI:10.1200/JCO.2000.18.16.2981.
[3] Arriagada R, Bengt B, Ariane D, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer[J]. New Engl J Med, 2004, 350(4):351-360. DOI:10.1056/NEJMoa031644.
[4] Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer[J]. N Engl J Med, 2005, 352(25):2589-2597. DOI:10.1056/NEJMoa043623.
[5] Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association[ANITA]):a randomised controlled trial[J]. Lancet Oncol, 2006, 7(9):719-727. DOI:10.1016/S1470-2045(06)70804-X.
[6] PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer:systematic review and meta-analysis of individual patient data from nine randomised controlled trials[J]. Lancet, 1998, 352(9124):257-263.
[7] PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2005(2): D2142. DOI:10.1002/14651858. CD002142.pub2.
[8] Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors[J]. Recen. Results Cancer Res, 2000, 157:55-81. DOI:10.1007/978-3-642-57151-0_6.
[9] Ichinose Y, Harubumi K, Teruaki K, et al. Overall survival and local recurrence of 406 completely resected stage Ⅲ a-N2 non-small cell lung cancer patients:questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials[J]. Lung Cancer, 2001, 34(1):29-36. DOI:10.1016/S0169-5002(01)00207-0.
[10] Matsuguma H, Nakahara R, Ishikawa Y, et al. Postoperative radiotherapy for patients with completely resected pathological stage ⅢA-N2 non-small cell lung cancer:focusing on an effect of the number of mediastinal lymph node stations involved[J]. Interact CardioVascul Thorac Surg, 2008, 7(4):573-577. DOI:10.1510/icvts.2007.174342.
[11] 陈建武,张幸平,曾奕明,等. Ⅲ a (N_2)期非小细胞肺癌术后放疗疗效分析[J]. 重庆医科大学学报, 2009, 34(11):1566-1570. DOI:10.13406/j.cnki.cyxb.2009.11.035.
[12] 田翠孟,张旭,夏广荣,等. pN-2-ⅢA期非小细胞肺癌患者的术后生存状况和预后因素分析[J]. 临床肿瘤学杂志, 2018, 23(12):1107-1113. DOI:10.3969/j.issn.1009-0460.2018.12.010.
[13] Yuan C, Tao X, Zheng D, et al. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive ⅢA non-small cell lung cancer[J]. J Surg Oncol, 2019, 119(3):379-387. DOI:10.1002/jso.25308.
[14] Wang S, Ma Z, Yang X, et al. Choice of postoperative radiation for stage ⅢA pathologic N2 non-small cell lung cancer:impact of metastatic lymph node number[J]. Radiat Oncol, 2017, 12(1):207-216. DOI:10.1186/s13014-017-0946-1.
[15] Shang XL, Li ZX, Lin JM, et al. PLNR≤20% may be a benefit from PORT for patients with ⅢA-N2 NSCLC:a large population-based study[J]. Cancer Manag Res, 2018, 10(9):3561-3567. DOI:10.2147/CMAR. S173856.
[16] Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy[J]. Front Oncol, 2012, 28:1-7. DOI:10.3389/fonc.2012.00095.
[17] Kepka L, Krzysztof B, Orlowski TM, et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy[J]. Radiother Oncol, 2011, 98(2):238-243. DOI:10.1016/j.radonc.2010.09.020.
[18] Billiet C, Herbert D, Stephanie P, et al. Modern post-operative radiotherapy for stage Ⅲ non-small cell lung cancer may improve local control and survival:a meta-analysis[J]. Radiother Oncol, 2014, 110(1):3-8. DOI:10.1016/j.radonc.2013.08.011.
[19] Wen F, Zhang Q, Fu XL, et al. The emerging outcome of postoperative radiotherapy for stage ⅢA(N2) non-small cell lung cancer patients:based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume[J]. BMC cancer, 2015, 15(1):348-358. DOI:10.1186/s12885-015-1326-6.
[20] Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy:a review of the National Cancer Data Base[J]. J Clin Oncol, 2015, 33(8):870-876. DOI:10.1200/JCO.2014.58.5380.
[21] Wang HH, Deng L, Wen QL, et al. Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage ⅢA-N2 non-small cell lung cancer[J]. Oncotarget, 2017, 8(38):62998-63013. DOI:10.18632/oncotarget.18071.
[22] Sakurai H, Asamura H, Miyaoka E, et al. Differences in the prognosis of resected lung adenocarcinoma according to the histological subtype:a retrospective analysis of Japanese lung cancer registry data[J]. Eur J Cardiothorac Surg, 2014, 45(1):100-107. DOI:10.1093/ejcts/ezt284.
[23] Hui Z, Dai H, Liang J, et al. Selection of proper candidates with resected pathological stage ⅢA-N2 non-small cell lung cancer for postoperative radiotherapy[J]. Thorac Cancer, 2015, 6(3):346-353. DOI:10.1111/1759-7714.12186.
[24] Moretti L, Yu DS, Chen H, et al. Prognostic factors for resected non-small cell lung cancer with pN2 status:implications for use of postoperative radiotherapy[J]. Oncologist, 2009, 14(11):1106-1115. DOI:10.1634/theoncologist.2009-0130.
[25] Dai H, Hui Z, Ji W, et al. Postoperative radiotherapy for resected pathological stage Ⅲ a-N2 non-small cell lung cancer:a retrospective study of 221 cases from a single institution[J]. Oncologist, 2011, 16(5):641-650. DOI:10.1634/theoncologist.2010-0343.
[26] Hsu HC, Wang CJ, Huang EY, et al. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement:outcome and prognostic factors[J]. Br J Radiol, 2004, 77(913):43-48. DOI:10.1259/bjr/21845347.
[27] 杜芳芳,袁智勇,王军,等. 术后放疗在PN2期非小细胞肺癌中的地位[J]. 中国肺癌杂志, 2009, 12(11):1164-1168. DOI:10.3779/j.issn.1009-3419.2009.11.07.
[28] Hanagiri T, Sugio K, Mizukami M, et al. Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(10):1127-1132. DOI:10.1097/JTO.0b013e318186fafb.
[29] Ferketich AK, Niland JC, Mamet R, et al. Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort[J]. Cancer, 2013, 119(4):847-853. DOI:10.1002/cncr.27824.
[30] Kogure Y, Ando M, Saka H, et al. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L[J]. J Thorac Oncol, 2013, 8(6):753-758. DOI:10.1097/JTO.0b013e31828b51f5.
[31] Jana LF, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer[J]. Lung Cancer, 2004, 44(3):287-293. DOI:10.1016/j.lungcan.2003.11.012.
[32] Nguyen SNA, Masson-CôtéL,AndréF, et al. Influence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancer[J]. Radiother Oncol, 2010, 96(1):89-93. DOI:10.1016/j.radonc.2010.05.008.
[33] Imbriani M, Melotti A, Ghittori S. Methemoglobin and carboxyhemoglobin levels in smokers and non smokers[J]. G Ital Med Lav, 1987, 9(1):11-14.
[34] Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance, epidemiology, and end results database[J]. J Clin Oncol, 2006, 24(19):2998-3006. DOI:10.1200/JCO.2005.04.6110.
[35] Kou P, Wang HY, Lin JM, et al. Male patients with resected ⅢA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy:a population-based survival analysis[J]. Future Oncol, 2018, 14(23):2371-2381. DOI:10.2217/fon-2018-0326.
[36] Wen ZZ, Wang J, Wang Q, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA(N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104):a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018, 19(1):139-148. DOI:10.1016/S1470-2045(17)30729-5.
[37] Dong SY, Xu SD, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN):a randomised, open-label, phase 2 trial[J]. Lancet Respirat Med, 2018, 6(11):863-873. DOI:10.1016/S2213-2600(18)30277-7.
[38] Ono A, Mitsuhiro I, Masakuni S, et al. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer[J]. Lung Cancer, 2019, 128(2):152-157. DOI:10.1016/j.lungcan.2018.12.005.